Transcatheter edge-to-edge repair yields variable long-term durability for tricuspid regurgitation, with late recurrence often driven by ongoing right-sided chamber remodeling.
What are the determinants of procedural success, mechanisms of recurrent TR, and clinical impacts of transcatheter edge-to-edge repair in patients with significant tricuspid regurgitation?
TEER is an effective therapeutic option for significant tricuspid regurgitation that improves symptoms and renal function, though late recurrence driven by right-sided chamber remodeling remains a significant limitation.
Absolute Event Rate: 0% vs 0%
Transcatheter edge-to-edge repair (TEER) has emerged as an important therapeutic option for patients with significant tricuspid regurgitation (TR), yet procedural success and long-term durability remain variable. Early TR reduction is influenced by anatomic complexity, leaflet coaptation mechanics, and device-related factors, whereas late recurrence is often driven by ongoing right-sided chamber remodeling and leaflet-clip interactions. Although contemporary registries demonstrate sustained TR improvement in many patients, a notable subset experiences recurrent TR with adverse clinical outcomes. A comprehensive understanding of the determinants of procedural success, mechanisms of residual or recurrent TR, and their downstream impact on heart failure, renal function, and survival is essential to refining patient selection and optimizing timing of intervention.
Ganni et al. (Sun,) ont rapporté un autre. La réparation par l'approche par voie transfémorale edge-to-edge offre une durabilité variable à long terme pour la régurgitation tricuspidienne, avec une récidive tardive souvent due à une remodelage continu des cavités droites.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: